Zambia gets new HIV shot, but questions about access remain

Zambia received 1,000 doses of the new Lenacapavir injection, a long-acting HIV prevention drug. This is part of a larger rollout aimed at improving access compared to daily pills.
By Newsroom | Health, Africa |

Zambia and Eswatini have received the initial shipments of Lenacapavir, a new long-acting injectable drug designed to prevent HIV infection. This marks a significant development in the global health strategy to combat the epidemic, particularly in regions with high HIV burdens. The drug, administered every six months, offers a potential alternative to daily pill regimens for pre-exposure prophylaxis (PrEP).

A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It? - 1

The delivery of Lenacapavir to Zambia is framed as a milestone, with officials highlighting its potential to reach individuals struggling with adherence to daily medications. However, concerns linger regarding the drug's actual accessibility, with critics pointing to insufficient initial quantities and potential affordability issues that could hinder widespread adoption.

A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It? - 2

International Collaboration and Ambitious Targets

The initiative involves a multi-partner effort, spearheaded by the President’s Emergency Plan for AIDS Relief (PEPFAR), in conjunction with the U.S. Department of State, Gilead Sciences (the drug's manufacturer), and the Global Fund to Fight HIV, Tuberculosis and Malaria. Peter Sands, Executive Director of the Global Fund, stressed the need for community-centered delivery to effectively reach those at high risk. Jeremy Lewin, a senior official with the State Department, indicated that the U.S. government anticipates procuring over half a million doses collectively in the coming year, aiming for substantial procurement by mid- to early 2027.

Read More: Trump's Third Walter Reed Visit May 26 Sparks Health Questions

A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It? - 3

Challenges and Criticisms in Drug Distribution

Despite the lauded arrival of the drug, past actions by the U.S. government, specifically foreign aid cuts, have been cited as detrimental to the very systems essential for delivering such medications to vulnerable populations. This has reportedly created a deficit that complicates current distribution efforts. While governments are increasingly relying on community and non-governmental organizations, the scale of the initial delivery – 1,000 doses to Zambia and Eswatini combined – has been described by some as falling far short of the actual need.

Read More: Why online shows Africa as sex images or just facts: How this hurts its real image today

A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It? - 4

Regulatory Approval and Local Impact

Zambia has officially registered Lenacapavir, becoming the second country in Africa, after South Africa, to do so. Health officials in Zambia have emphasized the drug's potential to significantly impact the country's prevention efforts, which grapple with approximately 30,000 new infections annually, disproportionately affecting adolescent girls and young women. The semi-annual injection is seen as a promising option for those who prefer privacy in accessing prevention or face difficulties with daily regimens, including pregnant and breastfeeding mothers at risk.

Background and Drug Specifics

Lenacapavir, marketed as Yeztugo, is an injectable antiretroviral drug. It is crucial to note that the drug is intended for HIV prevention only in individuals confirmed to be HIV-negative. Using Yeztugo alone for individuals who already have HIV-1 is not a complete treatment regimen and could lead to the emergence of drug resistance. The initial clinical trials for the drug were conducted in Sub-Saharan Africa, where HIV prevalence is highest. The drug's rollout in Africa aims to move beyond the limitations of daily PrEP pills, which have historically constrained the impact on global infection rates.

Read More: Ibiza Club Owner Loses £30,000 and Bentley Due to Alcoholism

Frequently Asked Questions

Q: What is the new HIV prevention drug that arrived in Zambia?
The new drug is Lenacapavir, also known as Yeztugo. It is an injectable medicine given every six months to prevent HIV infection in people who are HIV-negative.
Q: Why is Lenacapavir important for Zambia?
Zambia has about 30,000 new HIV infections each year, especially among young women. This new shot could help people who find it hard to take daily HIV prevention pills.
Q: Who is getting the first doses of Lenacapavir in Zambia?
Zambia received 1,000 doses of Lenacapavir, along with Eswatini. The drug is meant for people at high risk of HIV infection who prefer an injection over daily pills.
Q: Are there any problems with getting Lenacapavir in Zambia?
Yes, some people worry that the first delivery of 1,000 doses is not enough for everyone who needs it. There are also questions about how affordable the drug will be for widespread use.